ArticlePloS one2025
Estimation of the heritability of medicinal compound contents in Glycyrrhiza uralensis.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glycyrrhiza uralensis Fischer (Fabaceae), an important medicinal plant widely used in traditional Japanese and Chinese medicine, contains bioactive compounds, such as glycyrrhizin and flavonoids, which exhibit pharmacological activities, including antispasmodic and antitussive effects. Overharvesting has depleted wild populations, making the cultivation of G. uralensis necessary to stabilize its supply; however, the content of bioactive compounds tends to decrease in cultivated plants. In this study, we investigated the genetic inheritance (heritability) of medicinal compound contents in G. uralensis by analyzing clonal lines propagated from stolons. Broad-sense heritability was estimated for seven medicinal compounds using 26 clonal lines, revealing high heritability for glycyrrhizin and several flavonoids. In addition, correlation analyses between seed-derived and stolon-derived roots demonstrated strong genetic inheritance of these compounds. Furthermore, the effects of plant age and cultivation year on compound content were examined. Our results show high correlations between compound content and genotype across plant age (one- and two-year-old plants), suggesting the feasibility of early selection in breeding programs. While environmental variations influenced absolute compound levels, the relative rankings among genotypes remained stable. These results indicate the high heritability of compound contents and the strong effectiveness of selective breeding. We conclude that there is strong potential for selective breeding to enhance the medicinal quality of G. uralensis by targeting high-yielding genotypes with superior compound profiles and that this potential may also apply to the sustainable cultivation of other high-quality medicinal plant resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.